Seroatlas · Human Serome Atlas

SLC13A3

Na(+)/dicarboxylate cotransporter 3

Also known as: NADC3, S13A3_HUMAN, SDCT2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8WWT9
Gene
SLC13A3
Ensembl
ENSG00000158296
Chromosome
20
Canonical length
602 aa
Protein class
Disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Subcellular location
Plasma membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

Mammalian sodium-dicarboxylate cotransporters transport succinate and other Krebs cycle intermediates. They fall into 2 categories based on their substrate affinity: low affinity and high affinity. Both the low- and high-affinity transporters play an important role in the handling of citrate by the kidneys. The protein encoded by this gene represents the high-affinity form. Alternatively spliced transcript variants encoding different isoforms have been found for this gene, although the full-length nature of some of them have not been characterized yet. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

602 residues, UniProt reviewed canonical sequence.

>Q8WWT9|SLC13A3
     1  MAALAAAAKK VWSARRLLVL LFTPLALLPV VFALPPKEGR CLFVILLMAV YWCTEALPLS
    61  VTALLPIVLF PFMGILPSNK VCPQYFLDTN FLFLSGLIMA SAIEEWNLHR RIALKILMLV
   121  GVQPARLILG MMVTTSFLSM WLSNTASTAM MLPIANAILK SLFGQKEVRK DPSQESEENT
   181  AAVRRNGLHT VPTEMQFLAS TEAKDHPGET EVPLDLPADS RKEDEYRRNI WKGFLISIPY
   241  SASIGGTATL TGTAPNLILL GQLKSFFPQC DVVNFGSWFI FAFPLMLLFL LAGWLWISFL
   301  YGGLSFRGWR KNKSEIRTNA EDRARAVIRE EYQNLGPIKF AEQAVFILFC MFAILLFTRD
   361  PKFIPGWASL FNPGFLSDAV TGVAIVTILF FFPSQRPSLK WWFDFKAPNT ETEPLLTWKK
   421  AQETVPWNII LLLGGGFAMA KGCEESGLSV WIGGQLHPLE NVPPALAVLL ITVVIAFFTE
   481  FASNTATIII FLPVLAELAI RLRVHPLYLM IPGTVGCSFA FMLPVSTPPN SIAFASGHLL
   541  VKDMVRTGLL MNLMGVLLLS LAMNTWAQTI FQLGTFPDWA DMYSVNVTAL PPTLANDTFR
   601  TL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC13A3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
11
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
380 nTPM

Expression across tissuesHPA

Tissue

  • kidney: 380 nTPM
  • placenta: 41 nTPM
  • liver: 20 nTPM
  • spinal cord: 20 nTPM
  • midbrain: 13 nTPM
  • cerebral cortex: 8.9 nTPM

Single-cell type

  • proximal tubule cells: 1,347 nCPM
  • cytotrophoblasts: 289 nCPM
  • oligodendrocytes: 204 nCPM
  • syncytiotrophoblasts: 128 nCPM
  • late spermatids: 126 nCPM
  • astrocytes: 97 nCPM

Immune cell

  • basophil: 0.8 nTPM
  • plasmacytoid DC: 0.5 nTPM
  • neutrophil: 0.2 nTPM
  • classical monocyte: 0.1 nTPM
  • gdT-cell: 0.1 nTPM
  • naive B-cell: 0.1 nTPM

Brain region

  • white matter: 79 nTPM
  • basal ganglia: 51 nTPM
  • thalamus: 45 nTPM
  • midbrain: 45 nTPM
  • pons: 43 nTPM
  • medulla oblongata: 42 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC13A3.

Disease | AllUniProt

Conditions SLC13A3 is implicated in, by any mechanism.

  • Leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate (ARLIAK) MIM:618384

Disease | GeneticClinVar

4 pathogenic / likely-pathogenic of 243 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.83
gnomAD pLI
0
gnomAD missense Z
1.4
DepMap mean gene effect
0.01
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC13A3 as an antibody target. Whether an autoantibody or antibody against SLC13A3 could matter depends on whether native SLC13A3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC13A3 is annotated at the cell surface, where native SLC13A3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC13A3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC13A3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...